Boston Scientific - BSX Stock Forecast, Price & News

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. BTIG Research increased their price target on Boston Scientific from $45.00 to $50.00 and gave the company a "buy" rating in a report on Thursday, July 28th. Canaccord Genuity Group decreased their price target on Boston Scientific from $51.00 to $43.00 and set a "buy" rating for the company in a report on Wednesday, June 29th. StockNews.com cut Boston Scientific from a "buy" rating to a "hold" rating in a research report on Thursday, April 21st. Wolfe Research assumed coverage on Boston Scientific in a report on Tuesday, July 5th. They issued an "outperform" rating and a $43.00 price objective on the stock. Finally, Morgan Stanley reduced their target price on Boston Scientific from $51.00 to $46.00 and set an "overweight" rating on the stock in a research note on Friday, July 15th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $46.55.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $41.76 on Friday. The stock's fifty day simple moving average is $38.35 and its 200 day simple moving average is $41.25. The company has a market capitalization of $59.70 billion, a PE ratio of 71.81, a PEG ratio of 2.22 and a beta of 0.85. The company has a current ratio of 1.31, a quick ratio of 0.86 and a debt-to-equity ratio of 0.51. Boston Scientific has a 12 month low of $34.98 and a 12 month high of $47.49.

Boston Scientific (NYSE:BSX - Get Rating) last announced its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.02. The company had revenue of $3.24 billion during the quarter, compared to analysts' expectations of $3.22 billion. Boston Scientific had a return on equity of 14.58% and a net margin of 7.16%. Boston Scientific's revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.40 EPS. On average, research analysts predict that Boston Scientific will post 1.76 EPS for the current year.

Insider Buying and Selling at Boston Scientific

In related news, Director Nelda J. Connors sold 16,088 shares of the business's stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $41.58, for a total value of $668,939.04. Following the sale, the director now owns 4,877 shares of the company's stock, valued at $202,785.66. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Nelda J. Connors sold 16,088 shares of the business's stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $41.58, for a total value of $668,939.04. Following the transaction, the director now owns 4,877 shares in the company, valued at $202,785.66. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Wendy Carruthers sold 7,500 shares of the company's stock in a transaction dated Friday, June 24th. The shares were sold at an average price of $38.00, for a total transaction of $285,000.00. Following the transaction, the executive vice president now owns 132,413 shares in the company, valued at approximately $5,031,694. The disclosure for this sale can be found here. Insiders sold a total of 59,264 shares of company stock worth $2,382,173 over the last three months. Corporate insiders own 0.71% of the company's stock.